Apple Stock Downgraded by KeyBanc on Slowing iPhone Demand and Stretched Valuation
KeyBanc turns bearish on Apple, cutting the stock to Underweight and setting a $250 target. Analyst flags softening demand, iPhone headwinds, and rich valuation.
/ 220 items
#andre↓
MBX Biosciences Appoints Steve Hoerter as Chairman and CEO, John Smither as CFO
The moves are aimed at supporting the company’s next phase of growth in precision peptide therapies.
Agenus Secures Up to $340M to Fund Pivotal Phase 3 ROBBIN Trial in Neoadjuvant Colon Cancer
H.C. Wainwright boosts Agenus’ price target to $30 from $23, reiterating a Buy rating.
FDA Approves First At-Home Starting Dose for Leqembi Alzheimer’s Treatment
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).
Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
Oncolytics Biotech Advances REO 033 Trial with Promising Pelareorep Data in Hard-to-Treat Colorectal Cancer
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.